Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT02500914
Official study title

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Study summary

This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSC-002

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC) · Recurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 5, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Stemcentrx

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Stemcentrx
Interventions being studied
Drug: SC-002
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
Disease setting
Recurrent or relapsed→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment
  • Evidence of progressive disease during or following no more than 2 prior chemotherapy regimens
  • Measurable disease as defined by RECIST
  • ECOG performance status of 0 or 1
  • Adequate hematological and organ function as confirmed by laboratory values
  • Treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose of SC-002
Reasons someone may not be able to joinExclusion criteria
  • Active central nervous system metastases
  • Uncontrolled cardiac disease
  • Positive serology for hepatitis B or hepatitis C or known HIV infection
  • Presence of any condition that may increase the risks associated with study participation and interfere with the interpretation of study results

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Study locationAnn Arbor, Michigan
  • Study locationSt Louis, Missouri
  • Study locationNew York, New York
  • Study locationNashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 5, 2018. Always confirm current availability with the study team.

View original record ↗